TVM Capital has found a fifth compound to put into its growing stable of asset-focused newcos, the new strategy it is pursuing for TVM Life Science Ventures VII.

The new biotech, FAAH Pharma Inc., is developing a fatty acid amide hydrolase (FAAH) inhibitor for pain that TVM's Cynthia Lavoie said has "good demonstration in analgesia without some of the negative side effects of inhibiting that receptor."